ID   NZOV11
AC   CVCL_D810
SY   NZOV-11; New Zealand OVarian line 11
DR   cancercelllines; CVCL_D810
DR   Wikidata; Q54931646
RX   PubMed=7718330;
RX   PubMed=19493612;
RX   PubMed=21912889;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=21912889).
CC   Miscellaneous: This cell line was orginally classified as originating from an ovarian serous surface papillary adenocarcinoma and has been reclassified as a peritoneal serous papillary adenocarcinoma The reason being that serous surface papillary adenocarcinoma is no longer considered an ovarian primary tumor. The assumption is that all cases have peritoneal primaries.
CC   Derived from site: Metastatic; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7695; Primary peritoneal serous papillary adenocarcinoma
DI   ORDO; Orphanet_168829; Primary peritoneal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   31Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 13
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.L.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31A:230-237(1995).
//
RX   PubMed=19493612; DOI=10.1016/j.canlet.2009.05.010;
RA   Ramachandran A., Marshall E.S., Love D.R., Baguley B.C.,
RA   Shelling A.N.;
RT   "Activin is a potent growth suppressor of epithelial ovarian cancer
RT   cells.";
RL   Cancer Lett. 285:157-165(2009).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//